

General Information

Name: Prof. Dr. med. Christian Buske
Date of Birth: 26.08.1965
Gender: Male
Address: Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm
James-Franck-Ring (N27), 89081 Ulm, Germany
Phone: +49 731 50 65801 / 888 (office)
E-Mail: christian.buske@uni-ulm.de
Current Position: Medical Director, Institute of Experimental Cancer Research, Ulm University
Children: 3

Academic Education

1993 Thesis in Medicine (Hematology/Oncology) (Dr. med.)
1985-1992 Medical Study, Westfälische- Wilhelms-Universität, Münster

Academic Degrees

MD, Professor

Professional Experience

Since 2009 Medical Director – CCC Ulm/Institute of Experimental Cancer Research, Ulm University, Attending physician University Hospital Ulm
2004-2009 Attending physician Med. Clinic III, Klinikum Großhadern, Munich
2003 Venia legendi for Internal Medicine (Habilitation)
2003 Consultant in Internal Medicine
2001-2004 Postdoctoral Fellowship Med. Clinic III, Klinikum Großhadern, Munich
1998-2001 BCCA Vancouver, Canada
1992-1997 Medical Fellowship Medizinische Klinik, Georg-August-Universität Göttingen

Miscellaneous

Honors and awards

2000 Canadian Research Award 2000
2000 First Prize Young Investigator Award: 29st Annual Meeting of the International Society for Experimental Hematology (ISEH)
1998-2000 Postdoctoral fellowship of German Research Council (DFG)
1987-1992 Stipend, Studienstiftung des Deutschen Volkes

Membership in advisory boards

Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
Deutsche Gesellschaft für Innere Medizin (DGIM)
American Society of Hematology (ASH)

International Society for Hematology and Stem Cells (ISEH)
European Society for Medical Oncology (ESMO)

Editorial Boards

Leukemia, Experimental Hematology

Reviewer Journals

Science, NEJM, Cancer Cell, Cell Stem Cell, JCI, Blood,
Cancer Research, Oncology, New England Journal of Medicine

Funding

DFG, Deutsche Krebshilfe, BMBF, Else-Kröner-Fresenius-Stiftung

Committees

Coordinator 'European Consortium for Waldenström's
Macroglobulinemia (ECWM)
Chair 'Early Trials Network' (ETN)
Co-Coordinator 'German National Marginal Zone Lymphoma Registry'
Chair ESMO Working Party on Hematological Neoplasms
Chair DGHO Clinical Guidelines on indolent B – NHL
Steering Committee 'GLSG' (German Low Grade Lymphoma Study
Group)

Publications and Patents

1. Edmaier KE, Stahnke K, Vegi N, Mulaw M, Ihme S, Scheffold A, Rudolph KL, Buske C. Expression of the lymphoid enhancer factor 1 is required for normal hematopoietic stem and progenitor cell function. **Leukemia**. 2014;28:227-30.
2. Stadler CR, Vegi N, Mulaw MA, Edmaier KE, Rawat VP, Dolnik A, Bullinger L, Heilmeier B, Quintanilla-Fend L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Feuring-Buske M, Buske C. The leukemogenicity of Hoxa9 depends on alternative splicing. **Leukemia**. 2014;28:1838-43.
3. Metzeler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Döhner K, Feuring-Buske M, Braess J, Spiekermann K, Buchner T, Sauerland MC, Döhner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. **Blood**. 2012;120:2118-26.
4. Rawat VP, Humphries RK, Buske C. Beyond Hox: the role of Para-Hox genes in normal and malignant hematopoiesis. **Blood**. 2012;120(3):519-27.
5. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poepl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, Golub TR, Jurisica I, Ebert BL, Dick JE. Stem cell gene expression programs influence clinical outcome in human leukemia. **Nat Med**. 2011;17(9):1086-93.
6. Rawat VP, Arseni N, Ahmed F, Mulaw MA, Thoene S, Heilmeier B, Sadlon T, D'Andrea RJ, Hiddemann W, Bohlander SK, Buske C, Feuring-Buske M. The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. **Proc Natl Acad Sci U S A**. 2010;107(39):16946-51.
7. Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland M-C, Heinecke A, Berdel WE, Büchner T, Wörmann B, Mansmann U, Braess J, Spiekermann K, Hiddemann W, Buske C* and Bohlander SK*. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: A comprehensive analysis of ERG, MN1 and BAALC transcript levels using oligonucleotide microarrays. **J Clin Oncol**. 2009;27(30):5031-38. *Equal contribution
8. Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VPS, Deshpande AJ, Heilmeier B, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C. A novel role for

Lef-1 as a central transcription mediator of Wnt signalling in leukemogenesis. **J Exp Med.** 2008;17(205):515-22.

9. Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, Macintyre E, Mecucci C, Ludwig WD, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. **Cancer Cell.** 2006;10:363-74.
10. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. **J Clin Invest.** 2005;115:2159-68.